NCT02435680 - Efficacy Study of MCS110 Given With Carboplatin and Gemcitabine in Advanced Triple Negative Breast Cancer (TNBC) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

August 10, 2015

Primary Completion Date

January 4, 2020

Study Completion Date

March 23, 2020

Conditions

Advanced Triple Negative Breast Cancer (TNBC) With High TAMs

Interventions

DRUG

MCS110

taken by I.V

DRUG

carboplatin

taken by I.V

DRUG

gemcitabine

taken by I.V

Trial Locations (23)

1090

Novartis Investigative Site, Vienna

1200

Novartis Investigative Site, Brussels

5020

Novartis Investigative Site, Salzburg

6009

Novartis Investigative Site, Nedlands

10002

Novartis Investigative Site, Taipei

10967

Novartis Investigative Site, Berlin

15706

Novartis Investigative Site, Santiago de Compostela

28050

Novartis Investigative Site, Madrid

35100

Novartis Investigative Site, Istanbul

40138

Novartis Investigative Site, Bologna

44805

Novartis Investigative Site, Saint-Herblain Cédex

45136

Novartis Investigative Site, Essen

72703

Highlands Oncology Group, Fayetteville

75231

Novartis Investigative Site, Paris

80131

Novartis Investigative Site, Napoli

02114

Massachusetts General Hospital Cancer Center SC, Boston

A-1090

Novartis Investigative Site, Vienna

01307

Novartis Investigative Site, Dresden

Unknown

Novartis Investigative Site, Hong Kong SAR

05505

Novartis Investigative Site, Seoul

03080

Novartis Investigative Site, Seoul

08035

Novartis Investigative Site, Barcelona

08041

Novartis Investigative Site, Barcelona